Project description
Real-world data to improve post-treatment in breast cancer
Meet REBECCA. This EU-funded project will use real-world data to improve post-treatment in breast cancer. It will also design guidelines and best practices for researchers and public health and regulatory bodies throughout Europe. As such, the project will move beyond the analysis of electronic health records, by combining this with detailed monitoring data from multiple wearables, online behaviour and registry data to monitor patients’ functional, emotional and quality of life trajectories. Specifically, REBECCA will focus on the complex array of chronic comorbidities developed during breast cancer recovery. However, the project will also demonstrate the extensibility of REBECCA to other forms of cancer. Findings will be disseminated widely to researchers and health bodies throughout Europe.
Objective
The REBECCA proposal aspires to tap into the potential of Real-world Data (RWD) for supporting groundbreaking clinical research on complex chronic conditions (CCC) as a complement to Randomised Controlled Trials (RCT). REBECCA moves beyond the analysis of Electronic health records (EHR), by combining it with detailed monitoring data from multiple wearable, online behaviour and registry data to monitor patients’ functional, emotional and Quality of Life trajectories, with high temporal granularity. REBECCA also proposes explainable causal modelling combined with deep learning to account for observed and latent confounders in RWD analysis. The project will focus on the complex array of chronic comorbidities developed during breast cancer recovery, in particular studying the impact of primary and adjuvant cancer treatment on patients’ quality of life and assessing the value of detailed patient monitoring as a means for improved patient care, but will also demonstrate the extensibility of REBECCA to other forms of cancer.
To this end, a total of seven studies in Sweden, Norway and Spain will produce new knowledge on clinical management of cancer patients that will shape future guidelines and practices for post-cancer treatments. Best practices resulting from the REBECCA studies will be disseminated to researchers, public health and regulatory bodies throughout Europe to facilitate wider adoption of RWD in clinical research. In addition, the REBECCA platform, capable of detailed monitoring and privacy-preserving federated cross-country data analysis, will provide an infrastructure for continued progress on use of RWD beyond the end of the project. Through these activities, REBECCA aims at the mass adoption of RWD for understanding CCCs and ultimately at establishing RWD as a valuable clinical research and patient management tool.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.5. - Methods and data
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
RIA - Research and Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SC1-BHC-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
546 36 THESSALONIKI
Greece
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.